Form 8-K - Current report:
SEC Accession No. 0001104659-21-104244
Filing Date
2021-08-12
Accepted
2021-08-12 17:06:49
Documents
16
Period of Report
2021-08-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2124117d4_8k.htm   iXBRL 8-K 28017
2 EXHIBIT 23.1 tm2124117d4_ex23-1.htm EX-23.1 2548
3 EXHIBIT 23.2 tm2124117d4_ex23-2.htm EX-23.2 3096
4 EXHIBIT 99.1 tm2124117d4_ex99-1.htm EX-99.1 659468
5 GRAPHIC tm2124117d4_ex23img001.jpg GRAPHIC 9889
  Complete submission text file 0001104659-21-104244.txt   965227

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA vyne-20210812.xsd EX-101.SCH 3215
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20210812_lab.xml EX-101.LAB 34593
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20210812_pre.xml EX-101.PRE 22730
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2124117d4_8k_htm.xml XML 3712
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 211168583
SIC: 2834 Pharmaceutical Preparations